收藏产品 产品信息
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human GCGR (Luc) HEK293 Reporter Cell was engineered to not only express CREB signaling response element, but also express the receptor full length human GCGR (Gene ID: 2642), which can drive luciferase expressing systems by GCGR agonists or Glucagon stimulation. In the absence of agonist or Glucagon, the GCGR receptor is not activated and luminescence signal is low. In the presence of agonist or Glucagon, the GCGR pathway-activated luminescence can be detected in a dose-dependent manner.
应用说明（Application）
• Screen for agonists that can bind and activate GCGR.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
培养基（Complete Growth Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
产品数据图
Receptor Assay
Expression analysis of human GCGR on Human GCGR (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human GCGR (Luc) HEK293 Reporter Cell or negative control cell using Alexa Fluor® 488-labeled anti-human GCGR antibody.
Protocol
Application
Bioactivity analysis of human GCGR agonist (RLU).
This reporter cell was incubated with serial dilutions of Retatrutide (a triple agonist peptide of GCGR, GIPR and GLP-1R). The EC50 of Retatrutide was approximately 0.024 nM.
Protocol
Bioactivity analysis of human GCGR agonist (FOLD).
This reporter cell was incubated with serial dilutions of Retatrutide (a triple agonist peptide of GCGR, GIPR and GLP-1R). The max induction fold was approximately 79.93.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human GCGR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Retatrutide (a triple agonist peptide of GCGR, GIPR and GLP-1R). Retatrutide stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 7-20.
Protocol
产品评论 发表评论
背景
G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.
靶点信息 
数据表和文档 
联系我们 
项目合作